Kong Peng Lam
Overview
Explore the profile of Kong Peng Lam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
410
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neo S, Tong L, Chong J, Liu Y, Jing X, Oliveira M, et al.
Sci Transl Med
. 2024 May;
16(747):eadi2952.
PMID: 38748775
Apart from their killer identity, natural killer (NK) cells have integral roles in shaping the tumor microenvironment. Through immune gene deconvolution, the present study revealed an interplay between NK cells...
2.
Loh H, Bin Mahfut F, Chen S, Huang Y, Huo J, Zhang W, et al.
MAbs
. 2023 Jul;
15(1):2231129.
PMID: 37403264
T-cell-engaging bispecific antibodies (T-bsAbs) are promising immunotherapies for cancer treatment due to their capability of redirecting T-cells toward destroying tumor cells. Numerous T-bsAb formats have been developed, each with advantages...
3.
Zhang B, Zhang B, Lai R, Sim W, Lam K, Lim S
Int J Mol Sci
. 2023 May;
24(9).
PMID: 37175803
Mesenchymal stem/stromal cell small extracellular vesicles (MSC-sEVs) have shown promise in treating a wide range of animal models of various human diseases, which has led to their consideration for clinical...
4.
Zhao J, Lee K, Toh H, Lam K, Neo S
Front Pharmacol
. 2023 Apr;
14:1163160.
PMID: 37063269
The dysregulation of the biochemical pathways in cancer promotes oncogenic transformations and metastatic potential. Recent studies have shed light on how obesity and altered lipid metabolism could be the driving...
5.
Zhang B, Huo J, Huang Y, Teo S, Duan K, Li Y, et al.
Vaccines (Basel)
. 2022 Jul;
10(7).
PMID: 35891221
The advent of the Omicron variant globally has hastened the requirement for a booster vaccination dose to confer continuous protection against symptomatic SARS-CoV2 infection. However, different vaccines are available in...
6.
Rada M, Althubiti M, Ekpenyong-Akiba A, Lee K, Lam K, Fedorova O, et al.
Oncotarget
. 2018 Jan;
8(63):106639-106647.
PMID: 29290977
p53 is a tumour suppressor that is activated in response to various types of stress. It is regulated by a complex pattern of over 50 different post-translational modifications, including ubiquitination...
7.
Loh W, Yang Y, Lam K
Biotechnol J
. 2017 Feb;
12(4).
PMID: 28146316
MicroRNAs (miRNAs) have emerged as promising targets for engineering of CHO cell factories to enhance recombinant protein productivity. Manipulation of miRNA levels in CHO cells have been shown to improve...
8.
Penny H, Sieow J, Adriani G, Yeap W, See Chi Ee P, Luis B, et al.
Oncoimmunology
. 2016 Sep;
5(8):e1191731.
PMID: 27622062
Patients with pancreatic ductal adenocarcinoma (PDAC) face a clinically intractable disease with poor survival rates, attributed to exceptionally high levels of metastasis. Epithelial-to-mesenchymal transition (EMT) is pronounced at inflammatory foci...
9.
Loh W, Loo B, Zhou L, Zhang P, Lee D, Yang Y, et al.
Biotechnol J
. 2014 May;
9(9):1140-51.
PMID: 24819042
MicroRNAs (miRNAs) are short, non-coding RNAs that can negatively regulate expression of multiple genes at post-transcriptional levels. Using miRNAs to target multiple genes and pathways is a promising cell-engineering strategy...
10.
Ng S, Tan T, Wang Y, Ng D, Goh L, Bardor M, et al.
PLoS One
. 2013 Jan;
7(12):e52785.
PMID: 23300776
Dectin-1 (CLEC7A) is a C-type lectin receptor that binds to β-glucans found in fungal cell walls to act as a major pattern recognition receptor (PRR). Since β-glucans epitope is not...